We are live on
!
Find out more
TECP
Trails Edge Capital Partners Portfolio holdings
AUM
$630M
This Fund
S&P 500
This Quarter
Est. Return
+16.76%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$630M
AUM Growth
+$193M
(+44%)
Cap. Flow
+$111M
Cap. Flow
% of AUM
17.7%
Top 10 Holdings %
Top 10 Hldgs %
50.32%
Holding
40
New
13
Increased
10
Reduced
7
Closed
5
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
TRAX
First Tracks Biotherapeutics
TRAX
|
+$28.3M |
| 2 |
BioMarin Pharmaceuticals
BMRN
|
+$28M |
| 3 |
Insmed
INSM
|
+$27.9M |
| 4 |
KLRA
Kailera Therapeutics
KLRA
|
+$21.6M |
| 5 |
Incyte
INCY
|
+$15.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vaxcyte
PCVX
|
+$38.5M |
| 2 |
DFTX
Definium Therapeutics
DFTX
|
+$32.9M |
| 3 |
Arcus Biosciences
RCUS
|
+$22.6M |
| 4 |
Revolution Medicines
RVMD
|
+$18.9M |
| 5 |
Mirum Pharmaceuticals
MIRM
|
+$11M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.15% |
| 2 | Financials | 0.85% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
IVA
26
Inventiva
IVA
$1.11B
| $10M | 1.6% |
2,657,997
| – | – |
|
27
CAMP4 Therapeutics
CAMP
$279M
| $8.45M | 1.34% |
1,932,937
-6,626
| -0.3% | -$28.6K |
|
28
Altimmune
ALT
$622M
| $8.09M | 1.28% |
+2,660,000
| New | +$7.94M |
|
29
Minerva Neurosciences
NERV
$239M
| $7.88M | 1.25% |
1,419,000
| – | – |
|
30
ProMIS Neurosciences
PMN
$138M
| $7.33M | 1.16% |
557,103
| – | – |
|
|
OKUR
31
OnKure Therapeutics
OKUR
$156M
| $6.56M | 1.04% |
+1,438,456
| New | +$6.17M |
|
32
Forte Biosciences
FBRX
$1.63B
| $5.81M | 0.92% |
+273,181
| New | +$6.48M |
|
|
RACC
33
Research Alliance Corp III
RACC
$200M
| $5.35M | 0.85% |
+500,000
| New | +$5.21M |
|
34
vTv Therapeutics
VTVT
$134M
| $3.21M | 0.51% |
85,192
-54,386
| -39% | -$1.89M |
|
|
IMA
35
ImageneBio Inc
IMA
$63M
| $1.66M | 0.26% |
+282,004
| New | +$1.59M |
|
36
Immunovant
IMVT
$8.99B
| – | – |
-414,054
| Closed | -$10.3M |
|
|
DFTX
37
Definium Therapeutics
DFTX
$6.02B
| – | – |
-1,738,110
| Closed | -$32.9M |
|
|
38
Vaxcyte
PCVX
$9.09B
| – | – |
-662,470
| Closed | -$38.5M |
|
|
39
Arcus Biosciences
RCUS
$4.02B
| – | – |
-1,047,935
| Closed | -$22.6M |
|
40
PUT
Xenon Pharmaceuticals
XENE
$5.85B
| – | – |
-200,000
| Closed | -$11.6M |
|
Similar funds
SJIC
SFO
PPC
ACGA
FAM
MC
GPTE
KNW
Trails Edge Capital Partners's Q2 2026 Portfolio in Review
As of Q2 2026, Trails Edge Capital Partners held 40 positions worth $630M, up 44% from $437M the previous quarter. Its ten largest holdings account for 50% of the portfolio.
Trails Edge Capital Partners deployed $111M of net new capital in Q2 2026, opening 13 new positions and adding to 10 existing holdings. Its largest new stake was First Tracks Biotherapeutics: 1,514,000 shares worth $30.5M.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 97% a quarter earlier, followed by Financials.
On the sell side, the largest reduction was Revolution Medicines, an estimated $18.9M trimmed.
- Trails Edge Capital Partners's largest Q2 2026 buy was First Tracks Biotherapeutics: 1,514,000 shares worth $30.5M.
- Trails Edge Capital Partners added most to Design Therapeutics in Q2 2026, an estimated $14.3M increase.
- Trails Edge Capital Partners's biggest Q2 2026 reduction was Revolution Medicines, cutting an estimated $18.9M.
- Trails Edge Capital Partners fully exited Vaxcyte in Q2 2026, selling an estimated $38.5M.
- Trails Edge Capital Partners's ten largest holdings make up 50% of its $630M portfolio in Q2 2026.
- Trails Edge Capital Partners opened 13 new positions and closed 5 in Q2 2026.
- Trails Edge Capital Partners's portfolio value rose 44% quarter-over-quarter to $630M.
Based on Trails Edge Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.